Table 10.

Pulmonary related adverse events in Study 2 in ≥3% of patients in any group.

Adverse Event	Placebo (n = 48)	OnabotA 240 U (n = 53)	OnabotA 360 U (n = 54)
Overall	9 (18.8%)	14 (26.4%)	15 (27.8%)
Upper respiratory tract infection	3 (6.3%)	4 (7.5%)	6 (11.1%)
Nasal congestion	0 (0.0%)	2 (3.8%)	2 (3.7%)
Nasopharyngitis	1 (2.1%)	1 (1.9%)	2 (3.7%)
Cough	2 (4.2%)	3 (5.7%)	0 (0.0%)
Rhinitis	0 (0.0%)	2 (3.8%)	0 (0.0%)